In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
Commentary: IFN-k is a rheostat for development of psoriasiform inflammation
University of Modena & Reggio Emiliana
Modena, Italy
PUBLICATION
IFN-k is a rheostat for development of psoriasiform inflammation. Gharaee-Kermani M, Estadt SN, Tsoi LC, Wolf-Fortune SJ, Liu J, Xing X, Theros J, Reed TJ, Lowe L, Gruszka D, Ward NL, Gudjonsson JE, Kahlenberg JM. J Invest Dermatol. 2022 Jan;142(1):155-165.e3. doi: 10.1016/j.jid.2021.05.029. Epub 2021 Aug 5. PMID: 34364883; PMCID: PMC8688309.
Why this article was chosen
Commentary
As pointed out by Garzorz-Stark and Kilian Eyerich1 in the Commentary related to the present article, in psoriatic skin, there are two immune axes involving IFNs: pDC-derived IFN-a and keratinocytes-derived IFN-k, both leading to type 1 (Th1, IL-12, and IFN-g) and type 3 (IL-23, Th17, IL-17) immune responses. This also implies an active role for keratinocytes in psoriasis.
Categories
Recent Posts
Getting to Know IPC’s Board Member Claudia de la Cruz: What Inspired Me to Specialize in Psoriasis
Introducing Our Latest IPC Councilors: Experts in Psoriasis Treatment and Research
Shining a Spotlight: Catching up with 2018 IPC Fellow, Jia Qi Chen, PhD
Also Read
Commentary: Looking Beyond Plaque Psoriasis: Novel IL-36 Inhibitor for Prevention of Generalized Pustular Psoriasis Flares
Discover the latest in generalized pustular psoriasis (GPP) treatment with the approval of intravenous spesolimab by regulatory authorities. Read about a 48-week study on the subcutaneous delivery of spesolimab, showcasing promising results for preventing GPP flares. Learn about the evolving landscape of GPP treatment.
Commentary: The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics
Nicole Ward explores groundbreaking psoriatic disease research methods published in recent literature. Discover how Spatial Transcriptomics and Single Cell Sequencing unveil new cellular players and pathways, opening doors to novel drug targets and advancing psoriasis research and medicine.
Commentary: Efficacy and Safety of Oral Roflumilast for Moderate to Severe Psoriasis—A Randomized Controlled Trial (PSORRO)
In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
Subscribe to the IPC Newsletter